InsiderTrades

Form 4 for PCRX Pacira BioSciences, Inc.

Accepted 2025-12-11 00:00:00 ET · period of report 2025-12-09 · accession 0001628280-25-056645 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-12-11 2025-12-09+ PCRX Cross Shawn CFO M - OptEx $16.45 +25.0K 72.1K +53% +$411.2K
DM 2025-12-11 2025-12-09+ PCRX Cross Shawn CFO S - Sale+OE $25.07 -25.0K 56.2K -31% -$626.8K
DM 2025-12-11 2025-12-09+ PCRX Cross Shawn CFO M - OptEx $0.00 -25.0K 175.0K -12% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-12-10 M A 9,104 $16.45 65,354 D — — (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
2 Common Common Stock 2025-12-09 M A 15,896 $16.45 72,146 D — — (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
3 Common Common Stock 2025-12-10 S D 9,104 $25.14 56,250 D — — (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive.
4 Common Common Stock 2025-12-09 S D 15,896 $25.03 56,250 D — — (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3.
5 Derivative Stock Option (Right to Buy) 2025-12-09 M D 15,896 $0.00 184,104 D $16.45 · — to 2034-11-04 15,896 Common Stock (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. (F4) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
6 Derivative Stock Option (Right to Buy) 2025-12-10 M D 9,104 $0.00 175,000 D $16.45 · — to 2034-11-04 9,104 Common Stock (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. (F4) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.